Devonian Health Group (GSD) Q3 2026 earnings summary

Executive summary

• Net loss for Q3 2026 was $1.9 million ($0.70 per share), a significant improvement from $4.8 million ($1.94 per share) in Q3 2025.

• Nine-month net loss totaled $5.7 million ($2.07 per share), slightly higher than $5.6 million ($2.28 per share) for the same period last year.

• Focus remains on advancing Thykamine™ for radiodermatitis prevention and atopic dermatitis in children, with ongoing research into its broader therapeutic potential.

Financial highlights

• Q3 net loss decreased by $2.9 million year-over-year, mainly due to the absence of a $4.8 million impairment loss recorded in the prior year.

• Nine-month net loss increased by $0.1 million year-over-year, primarily from a $6.5 million decrease in gross margin due to prior period Dexlansoprazole sales.

• Cash and cash equivalents stood at $0.7 million as of April 30, 2026, down from $7 million as of July 31, 2025.

Outlook and guidance

• Continued strategic focus on Thykamine™ development for radiodermatitis and atopic dermatitis in children.

• Ongoing evaluation of Thykamine™ for metabolic dysfunction-associated steatohepatitis (MASH) and fibrotic diseases.